Verition Fund Management
TVTX icon

Verition Fund Management’s Travere Therapeutics TVTX Stock Holding History

Verition Fund Management’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-56,010
Closed -$2.14M – 3554
2025
Q4 		$2.14M Buy
+56,010
New +$1.82M 0.01% 1546
2025
Q2 		– Sell
-73,454
Closed -$1.32M – 3875
2025
Q1 		$1.32M Sell
73,454
-2,854
-4% -$57.9K 0.01% 1905
2024
Q4 		$1.33M Buy
76,308
+15,437
+25% +$273K 0.01% 1846
2024
Q3 		$852K Buy
60,871
+32,583
+115% +$339K ﹤0.01% 1993
2024
Q2 		$233K Buy
+28,288
New +$191K ﹤0.01% 2505
2023
Q3 		– Sell
-10,050
Closed -$154K – 2688
2023
Q2 		$154K Buy
+10,050
New +$183K ﹤0.01% 1913

Other funds holding TVTX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Verition Fund Management's TVTX Position: Q1 2026 in Review

Verition Fund Management sold out of Travere Therapeutics (TVTX) in Q1 2026, closing a stake of 56,010 shares — an estimated $2.14M sold.

Verition Fund Management first reported a position in TVTX in Q2 2023 and held it in 6 quarters. The position peaked at $2.14M in Q4 2025. 260 funds tracked by Wall St. Rank hold TVTX as of Q1 2026.

  • Verition Fund Management reported no remaining Travere Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Verition Fund Management sold 56,010 Travere Therapeutics shares in Q1 2026, an estimated $2.14M.
  • Verition Fund Management first reported a position in Travere Therapeutics in Q2 2023 and held it in 6 quarters.
  • Verition Fund Management's Travere Therapeutics position peaked at $2.14M in Q4 2025.
  • 260 funds tracked by Wall St. Rank held Travere Therapeutics as of Q1 2026.

Based on Verition Fund Management's 13F filing for Q1 2026, filed 15 May 2026.